GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » EPS without NRI

Biomerica (Biomerica) EPS without NRI : $-0.37 (TTM As of Feb. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica EPS without NRI?

Biomerica's earnings per share without non-recurring items for the three months ended in Feb. 2024 was $-0.11. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.37.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -24.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -23.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Biomerica's EPS without NRI or its related term are showing as below:

BMRA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62   Med: -6.5   Max: 69.5
Current: -24.4

During the past 13 years, Biomerica's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 69.50% per year. The lowest was -62.00% per year. And the median was -6.50% per year.

BMRA's 3-Year EPS without NRI Growth Rate is ranked worse than
82.86% of 700 companies
in the Medical Devices & Instruments industry
Industry Median: 9.65 vs BMRA: -24.40

Biomerica's EPS (Diluted) for the three months ended in Feb. 2024 was $-0.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.37.

Biomerica's EPS (Basic) for the three months ended in Feb. 2024 was $-0.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.37.


Biomerica EPS without NRI Historical Data

The historical data trend for Biomerica's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica EPS without NRI Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.26 -0.62 -0.36 -0.50

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.10 -0.07 -0.09 -0.11

Competitive Comparison of Biomerica's EPS without NRI

For the Medical Devices subindustry, Biomerica's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Biomerica's PE Ratio without NRI falls into.



Biomerica EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomerica  (NAS:BMRA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biomerica EPS without NRI Related Terms

Thank you for viewing the detailed overview of Biomerica's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663

Biomerica (Biomerica) Headlines

From GuruFocus

Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

By Stock market mentor Stock market mentor 01-14-2023

Biomerica Reports Fiscal 2023 Year End Results

By GlobeNewswire 08-25-2023

Biomerica to Participate at BTIG Biotech Conference

By GuruFocusNews GuruFocusNews 06-23-2022